ECSP21069105A - Anticuerpos anti-trem2 y métodos para utilizarlos - Google Patents

Anticuerpos anti-trem2 y métodos para utilizarlos

Info

Publication number
ECSP21069105A
ECSP21069105A ECSENADI202169105A ECDI202169105A ECSP21069105A EC SP21069105 A ECSP21069105 A EC SP21069105A EC SENADI202169105 A ECSENADI202169105 A EC SENADI202169105A EC DI202169105 A ECDI202169105 A EC DI202169105A EC SP21069105 A ECSP21069105 A EC SP21069105A
Authority
EC
Ecuador
Prior art keywords
trem2
methods
trem2 antibodies
antibodies
antibody
Prior art date
Application number
ECSENADI202169105A
Other languages
English (en)
Inventor
Rachel Prorok
Kathryn M Monroe
Sherie Duncan
Ju Shi
Joshua I Park
Mark S Dennis
Ankita Srivastava
Kathleen Lisaingo
Lengerich Bettina Van
Riley Walsh
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of ECSP21069105A publication Critical patent/ECSP21069105A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

En un aspecto, se proporcionan anticuerpos que se unen específicamente a un receptor de activación expresado en la proteína de células mieloides 2 (TREM2). En algunas modalidades, el anticuerpo disminuye los niveles de TREM2 soluble (sTREM2). En algunas modalidades, el anticuerpo mejora la actividad de TREM2.
ECSENADI202169105A 2019-02-20 2021-09-17 Anticuerpos anti-trem2 y métodos para utilizarlos ECSP21069105A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962808141P 2019-02-20 2019-02-20

Publications (1)

Publication Number Publication Date
ECSP21069105A true ECSP21069105A (es) 2021-11-18

Family

ID=69844940

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202169105A ECSP21069105A (es) 2019-02-20 2021-09-17 Anticuerpos anti-trem2 y métodos para utilizarlos

Country Status (20)

Country Link
US (2) US20220073609A1 (es)
EP (1) EP3927743A1 (es)
JP (1) JP2022520868A (es)
KR (1) KR20210135518A (es)
CN (1) CN113614110A (es)
AR (1) AR118144A1 (es)
AU (1) AU2020226754A1 (es)
BR (1) BR112021015656A2 (es)
CA (1) CA3130086A1 (es)
CL (1) CL2021002206A1 (es)
CO (1) CO2021012230A2 (es)
EA (1) EA202192294A1 (es)
EC (1) ECSP21069105A (es)
IL (1) IL285651A (es)
MA (1) MA55025A (es)
MX (1) MX2021009722A (es)
PE (1) PE20211979A1 (es)
SG (1) SG11202108734VA (es)
TW (1) TW202045543A (es)
WO (2) WO2020172450A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
BR112022013756A2 (pt) 2020-01-13 2022-10-11 Denali Therapeutics Inc Anticorpos anti-trem2 e métodos de uso dos mesmos
BR112023023777A2 (pt) * 2021-05-14 2024-01-30 Genentech Inc Anticorpos isolados, composição farmacêutica, ácido nucleico isolado, vetor isolado, célula hospedeira isolada, método para produzir um anticorpo, método para tratar uma condição associada à perda de função de trem2, método para reduzir os níveis de strem2 e uso de um anticorpo
WO2023164516A1 (en) 2022-02-23 2023-08-31 Alector Llc Methods of use of anti-trem2 antibodies
WO2023192288A1 (en) 2022-03-28 2023-10-05 Denali Therapeutics Inc. Monovalent anti-trem2 binding molecules and methods of use thereof
WO2023192282A1 (en) 2022-03-28 2023-10-05 Denali Therapeutics Inc. Methods for treating brain glucose hypometabolism

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10087408B2 (en) 2010-07-07 2018-10-02 The University Of British Columbia System and method for microfluidic cell culture
US9188593B2 (en) 2010-07-16 2015-11-17 The University Of British Columbia Methods for assaying cellular binding interactions
SG10201913611QA (en) * 2014-08-08 2020-03-30 Alector Llc Anti-trem2 antibodies and methods of use thereof
CN114751989A (zh) * 2015-03-31 2022-07-15 豪夫迈·罗氏有限公司 包含三聚体tnf家族配体的抗原结合分子
WO2017058866A1 (en) * 2015-09-28 2017-04-06 Precision Immune, Inc. Anti-trem2 antibodies and uses thereof
KR20180068999A (ko) * 2015-10-06 2018-06-22 알렉터 엘엘씨 항-trem2 항체 및 그의 사용방법
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
BR112019022752A2 (pt) 2017-08-03 2020-05-19 Alector Llc anticorpos anti-trem2 e métodos de uso dos mesmos

Also Published As

Publication number Publication date
US20220119522A1 (en) 2022-04-21
CO2021012230A2 (es) 2021-09-30
IL285651A (en) 2021-09-30
US20220073609A1 (en) 2022-03-10
CN113614110A (zh) 2021-11-05
MA55025A (fr) 2021-12-29
JP2022520868A (ja) 2022-04-01
PE20211979A1 (es) 2021-10-05
MX2021009722A (es) 2021-09-14
AR118144A1 (es) 2021-09-22
WO2020172457A1 (en) 2020-08-27
WO2020172450A1 (en) 2020-08-27
EP3927743A1 (en) 2021-12-29
TW202045543A (zh) 2020-12-16
CA3130086A1 (en) 2020-08-27
SG11202108734VA (en) 2021-09-29
KR20210135518A (ko) 2021-11-15
BR112021015656A2 (pt) 2021-10-05
CL2021002206A1 (es) 2022-04-22
AU2020226754A1 (en) 2021-09-16
EA202192294A1 (ru) 2021-12-24

Similar Documents

Publication Publication Date Title
ECSP21069105A (es) Anticuerpos anti-trem2 y métodos para utilizarlos
CO2022009744A2 (es) Anticuerpos anti-trem2 y métodos para utilizarlos
CL2019003093A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos.
ES2527961T3 (es) Anticuerpos monoclonales humanos para CD70
CO2021006911A2 (es) Anticuerpos biespecíficos anti-pd-l1/anti-4-1bb y usos de los mismos
MX2020004129A (es) Anticuerpos anti-cd38 y metodos de uso.
CL2021001506A1 (es) Anticuerpos que se unen a cd3
UY37758A (es) Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
CL2022001886A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos
AR069775A1 (es) Anticuerpos bivalentes biespecificos
CL2021000909A1 (es) Anticuerpos estabilizadores de trem2
CO2021012719A2 (es) Métodos para producción de células car-nk y uso de las mismas
CR20160338A (es) Anticuerpos y métodos de uso
CO2021002954A2 (es) Anticuerpos anti-αvβ8 y composiciones y usos de los mismos
CO2022008272A2 (es) Agentes de unión a ilt3 y métodos de uso de los mismos
BR112021021645A2 (pt) Anticorpos anti-hvem e uso dos mesmos.
CL2021003563A1 (es) Anticuerpos para la unión a psma
DOP2022000129A (es) Anticuerpos contra la integrina alfa 11 beta 1
AR122930A1 (es) Anticuerpos de pre-direccionamiento y métodos de uso
AR112228A1 (es) Molécula de polipéptido con especificidad dual mejorada
CO2023015915A2 (es) Anticuerpos anti-ccr8
AR110908A1 (es) Constructo promotor para la síntesis de proteínas libre de células
CL2023001492A1 (es) Anticuerpos anti-ly6g6d y métodos de uso.
WO2019025865A3 (en) METHODS AND COMPOSITIONS FOR LIGAND-DIRECTED ANTIBODY DESIGN
CL2022000752A1 (es) Molécula de unión específica para lif y uso de la misma